<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cytek Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/cytek-biosciences-inc</link>
<description>Latest news and press releases for Cytek Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cytek-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355a7d78dffbe2df0eb7fd.webp</url>
<title>Cytek Biosciences Inc</title>
<link>https://6ix.com/company/cytek-biosciences-inc</link>
</image>
<item>
<title>Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investo</description>
</item>
<item>
<title>Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytekr-biosciences-celebrates-one-year-of-operations-at-singapore-facility-accelerating-growth-and-regional-impact</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytekr-biosciences-celebrates-one-year-of-operations-at-singapore-facility-accelerating-growth-and-regional-impact</guid>
<pubDate>Mon, 09 Mar 2026 21:00:00 GMT</pubDate>
<description>Anniversary Milestone Highlights Expanded Manufacturing Capacity, Stronger Asia-Pacific Presence, and Measurable Contributions to Global Supply Chain Resilience Cytek Singapore Facility Cytek Biosciences marks the one-year anniversary of its Singapore facility, a strategic hub that has strengthened the company's manufacturing capacity, expanded service and training capabilities across APAC, and bolstered global supply chain resilience. FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year</description>
</item>
<item>
<title>Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the</description>
</item>
<item>
<title>Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook </title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook-1</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook-1</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions</description>
</item>
<item>
<title>Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-to-participate-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-to-participate-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Cytek management is scheduled to participate in a hybrid presentation and fireside chat on Wednesday, March 4th at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentatio</description>
</item>
<item>
<title>Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-report-fourth-quarter-210500958</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-report-fourth-quarter-210500958</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available</description>
</item>
<item>
<title>Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-announces-preliminary-fourth-100000242</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-announces-preliminary-fourth-100000242</guid>
<pubDate>Mon, 12 Jan 2026 10:00:00 GMT</pubDate>
<description>Company to present at the 44th Annual JP Morgan Healthcare ConferenceFREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025. Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents gro</description>
</item>
<item>
<title>TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/time-recognizes-cytek-biosciences-one-220000031</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/time-recognizes-cytek-biosciences-one-220000031</guid>
<pubDate>Wed, 12 Nov 2025 22:00:00 GMT</pubDate>
<description>America's Growth Leaders Cytek Biosciences has been recognized by TIME as one of America’s Growth Leaders of 2026. Presented in partnership with global data firm Statista, the ranking recognizes the top-performing publicly listed companies in the United States that have demonstrated exceptional growth, financial stability, and stock performance over the past five years. FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today</description>
</item>
<item>
<title>Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-muse-micro-cell-analyzer-220000488</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-muse-micro-cell-analyzer-220000488</guid>
<pubDate>Thu, 06 Nov 2025 22:00:00 GMT</pubDate>
<description>BioTech Breakthrough Awards The Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards. FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards. The annual program, conducted by leading independent market intelligence organization BioTech Breakthro</description>
</item>
<item>
<title>Cytek Biosciences to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-participate-upcoming-investor-210500659</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-participate-upcoming-investor-210500659</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Global Healthcare Conference in Palm Beach, FLParticipating in investor 1x1 meetings on Tuesday, November 11, 2025 Stephens NASH25 Investment Conference in Nashville, TNFireside chat on November 19, 2025, at 9:00 a.m. Pacific Time /12:00 p.m. Eastern Time Piper Sandler 37t</description>
</item>
<item>
<title>Cytek Biosciences Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-third-quarter-210500490</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-third-quarter-210500490</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 20</description>
</item>
<item>
<title>Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-deepens-commitment-expanding-210000355</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-deepens-commitment-expanding-210000355</guid>
<pubDate>Wed, 29 Oct 2025 21:00:00 GMT</pubDate>
<description>Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants Cytek research initiative Cytek is supporting ISAC in a shared mission to extend flow cytometry reach worldwide. In this effort, Cytek has launched a two-part research initiative. In the first phase of the program, Cytek is awarding a three-laser Cytek Northern Lights™ flow cytometer. In the second phase, Cytek plans to launch a grant program to fund eligible research</description>
</item>
<item>
<title>Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-report-third-quarter-200500513</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-report-third-quarter-200500513</guid>
<pubDate>Wed, 22 Oct 2025 20:05:00 GMT</pubDate>
<description>FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investo</description>
</item>
<item>
<title>Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-expands-european-presence-210000379</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-expands-european-presence-210000379</guid>
<pubDate>Wed, 15 Oct 2025 21:00:00 GMT</pubDate>
<description>Cytek European Facility Cytek’s new facility in Amsterdam, The Netherlands, expands the company’s capacity to meet the growing demand for comprehensive cell analysis solutions. FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam’s Life Sciences Dist</description>
</item>
<item>
<title>Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-brings-full-spectrum-210000938</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-brings-full-spectrum-210000938</guid>
<pubDate>Wed, 10 Sep 2025 21:00:00 GMT</pubDate>
<description>Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and DiscoveryFREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced, high-parameter solutions at two notable industry events later this month: the European Society for Clinical Cell Analysis (ESCCA) 2025 Conference and ICCS 2025, the 40th</description>
</item>
<item>
<title>Cytek Biosciences Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-second-quarter-200500737</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-reports-second-quarter-200500737</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarte</description>
</item>
<item>
<title>Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-report-second-quarter-200500314</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-report-second-quarter-200500314</guid>
<pubDate>Wed, 23 Jul 2025 20:05:00 GMT</pubDate>
<description>FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investor</description>
</item>
<item>
<title>Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/mdxhealth-appoints-michael-holder-to-board-of-directors-and-announces-management-change</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/mdxhealth-appoints-michael-holder-to-board-of-directors-and-announces-management-change</guid>
<pubDate>Thu, 03 Jul 2025 17:00:00 GMT</pubDate>
<description>IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles</description>
</item>
<item>
<title>Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-setting-standard-full-210000162</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-setting-standard-full-210000162</guid>
<pubDate>Thu, 29 May 2025 21:00:00 GMT</pubDate>
<description>Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo Cytek today unveiled the Cytek Aurora™ Evo system, a full spectrum flow cytometer that builds on the trusted performance of the Cytek Aurora system. Designed to set a new standard in spectral flow cytometry, the Cytek Aurora Evo flow cytometer maintains the reproducibility researchers rely on, now with added high-throughput performance and automation capabilities. FREMONT, Calif., May 29, 2025 (GLOB</description>
</item>
<item>
<title>Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-participate-goldman-sachs-200500048</link>
<guid isPermaLink="true">https://6ix.com/company/cytek-biosciences-inc/news/cytek-biosciences-participate-goldman-sachs-200500048</guid>
<pubDate>Wed, 28 May 2025 20:05:00 GMT</pubDate>
<description>FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the</description>
</item>
</channel>
</rss>